During the past decade, MS Hub Medical Group conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "MS Hub Medical Group" are "Multiple Sclerosis" (2 trials) and "Relapse-Remitting Multiple Sclerosis" (1 trials). Many other conditions were trialed in "MS Hub Medical Group" in a lesser frequency.

Most popular intervention types in "MS Hub Medical Group" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)" (1 trials), "Fampridine-SR" (1 trials), "Placebo" (1 trials), "glatiramer acetate 20 mg" (1 trials) and "glatiramer acetate 40 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "MS Hub Medical Group" are 3 trials for "All" genders.

Currently, there are NaN active trials in "MS Hub Medical Group". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in MS Hub Medical Group, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in MS Hub Medical Group, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

MS Hub Medical Group has several departments that took part in Clinical trials: "MT Cancer Inst Fndtn; MT Can Spec" - 2 trials